Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. (Q30383012)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. (English)

1 reference

Europe PubMed Central

19 September 2017

0 references

pulmonary tuberculosis

1 reference

based on heuristic

inferred from title

object named as

Ronald G Hall

1

0 references

object named as

Tawanda Gumbo

3

0 references

author name string

Richard D Leff

2

1 reference

Europe PubMed Central

19 September 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

19 September 2017

Pharmacotherapy

1 reference

Europe PubMed Central

19 September 2017

29

1 reference

Europe PubMed Central

19 September 2017

12

1 reference

Europe PubMed Central

19 September 2017

1468-1481

1 reference

Europe PubMed Central

19 September 2017

Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

STREPTOMYCIN treatment of pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Mycobacterial efflux pumps and chemotherapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Treatment of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid drug and food interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Using therapeutic drug monitoring to dose the antimycobacterial drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Liver injury during antituberculosis treatment: an 11-year study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Pyridoxine supplementation during isoniazid therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Reversible pellagra-like encephalopathy with ethionamide and cycloserine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The role of pyrazinamide in tuberculosis chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Isoniazid induction of antinuclear antibodies. A prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

The nephrotoxicity of antimicrobial agents (second of three parts).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Basic Mechanisms of Chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

20 June 2018

Extensively drug-resistant tuberculosis in the United States, 1993-2007.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Toxic effect of streptomycin upon balance and hearing.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Pulmonary tuberculosis in patient on intermittent haemodialysis.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of Growth

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.12.1468

21 January 2018

THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

A comparison of isoniazid-cycloserine with isoniazid-PAS in the therapy of cavitary pulmonary tuberculosis. X. A report of the Veterans Administration-Armed Forces cooperative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Evidence of genetic transmission in African iron overload.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Effect of multiple staggered doses of calcium on the bioavailability of ciprofloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2862594

26 November 2018

Results of a surveillance system for adverse effects in leprosy's WHO/MDT

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elimination of para-aminosalicylic acid in patients with liver disease and renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EFFECTS of streptomycin on tuberculosis in man; preliminary statement

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pyrazinamide-isoniazid in tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A PILOT study of cycloserine toxicity; a United States Public Health Service Cooperative Clinical Investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TREATMENT of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PREVENTION of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amikacin in the treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ocular toxicity of ethambutol and its relation to dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amikacin-induced nephropathy: is there any protective way?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of pulmonary tuberculosis with increased dietary iron

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global epidemiology of tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19947806

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1592/PHCO.29.12.1468

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30383012&oldid=1628718284"